Safety of Biqi in biological science and Technology Co Ltd   

  safety of Biqi Biological Technology Co. Ltd. is a Service Corporation founded antibody research by a group of senior students returning staff. The company relies on the deep background of international resources, rich experience in the United States is committed to high-quality scientific research personnel antibody R & D service. Company's existing services include application of hybridoma technology for production of monoclonal antibodies, using phage display antibody, gene engineering and antibody affinity maturation, humanized antibodies related services. In addition, the company also provides a variety of services such as large-scale antibody expression, prokaryotic expression of scFv, Fab, bivalent antibody, IgG antibody, chimeric antibody, small molecular antibody mammalian cell expression, with a strong technological advantage and price advantage in the industry.

2010, monoclonal antibody of global sales will reach $26000000000, China will reach 5000000000 yuan in sales, in the next 10 years, monoclonal antibody drugs will become a world leader in the field of biological pharmacy, monoclonal antibody drugs in the future and has broad prospects for development. The factor that restricts the monoclonal antibody drug development is to overcome the high technique of gene engineering, so it has a strong R & D team will make your antibody drug R & D effort. An international research team by virtue of Biqi, antibody engineering patent technology first-class, and many well-known international pharmaceutical companies to cooperate in the development of projects, to build a good relationship of cooperation. Therefore, an they rely on strong technical support confidence into the global bio pharmaceutical market for Chinese pharmaceutical enterprises "approach". With our high quality services for customers to create high efficiency!

Production of monoclonal antibodies by hybridoma technique